



X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide Recent Business Highlights on March 12, 2020

February 27, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2020-- [X4 Pharmaceuticals, Inc.](#) (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced it will host a conference call and webcast to report its financial results for the fourth quarter and full year ended December 31, 2019 on March 12, 2020 at 8:30 a.m. ET.

The conference call can be accessed by dialing (866) 721-7655 (domestic) or (409) 216-0009 (international), followed by the conference ID: 3816258. The live webcast can be accessed on the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. The webcast replay will be available on the website approximately two hours after the completion of the call.

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company's oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4's most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is further investigating mavorixafor in a Phase 1b clinical trial for the treatment of Severe Congenital Neutropenia (SCN), and with ibrutinib for the treatment of Waldenström's macroglobulinemia (WM). X4 was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria. For more information, please visit www.x4pharma.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200227005235/en/): <https://www.businesswire.com/news/home/20200227005235/en/>

Investors and Media:

Candice Ellis, 857-341-1043
Director, Corporate Communications & Investor Relations
Candice.Ellis@x4pharma.com

Source: X4 Pharmaceuticals